Agenus AGEN
NASDAQ AGEN
$8.24 +0.00 (+0.00%)
As of: Sep 4, 2026 · 3:59 PM EDT

Agenus (AGEN) Long-Term Debt Repayments (2010 - 2026)

Agenus (AGEN) posted quarterly Long-Term Debt Repayments of $8.4 million for Q1 2026, up 236.52% year-over-year from $2.5 million in Q1 2025, and up 236.52% quarter-over-quarter from $2.5 million in Q1 2025.

Analysis

Agenus (AGEN) Long-Term Debt Repayments (2010 - 2026) Analysis & Trends

Agenus' Long-Term Debt Repayments history runs 6 years deep, the most recent figure standing at $8.4 million for Q1 2026.

  • In Q1 2026, Long-Term Debt Repayments rose 236.52% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (down 63.94% YoY), while the FY2025 annual figure was $2.5 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q1 2026 stood at $8.4 million, up from $2.5 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $8.4 million in Q1 2026, with the low at $2.5 million in Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 17.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Agenus 342.07 Mn 342.07 Mn 34.52 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 8.41 Mn
Mar 31, 2025 2.50 Mn
Mar 31, 2014 833,333.00
Dec 31, 2013 20.00 Mn
Jun 30, 2013 -10.00 Mn
Dec 31, 2012 100,000.00
Sep 30, 2012 -100,000.00
Jun 30, 2012 -7,521.00
Mar 31, 2012 7,521.00
Dec 31, 2010 6.24 Mn